Cannabinoid treatment specialists Emerald Clinics lists on ASX today

Cannabinoid treatment specialists Emerald Clinics lists on ASX today
© iStock/Sheng Li

Emerald Clinics, lists on the Australian Securities Exchange (ASX) today after raising $6 million in its Initial Public Offering (IPO).

Emerald Clinics is a company establishing and operating a network of clinics specialising in the appropriate use of unregistered medicines, including cannabinoids treatments, and the creation of robust and ethically sourced real world evidence.

The company has, to-date, established four patient focussed medical clinics in Sydney, Melbourne, Perth and the Northern Rivers region of NSW, providing safe access to unregistered medicines such as cannabinoid medicine for suitably qualified patients in collaboration with referring doctors.

Establishing clinics in the UK and Australia

Emerald issued 30 million new shares at $0.20 per share, giving it a market capitalisation of $36.8 million at listing. The funds raised in the IPO will assist Emerald in developing its data platform, establishing new clinics both across Australia as well as in the UK, conducting clinical trials and continuing to progress its business objectives including liaison with potential customers of the real-world data.

In addition to supporting patients to safely and appropriately trial unregistered medicines, the company’s trained cannabinoid treatment specialists co-create anonymous, trial-grade and regulator ready real-world evidence with their patients.

While the medicinal cannabis sector is gaining momentum globally, a lack of high-quality, product-specific, clinical evidence is constraining uptake by clinicians, authorisation from regulators and reimbursement by payors. Consequently, data and evidence gathered by the Company is in demand from treatment developers, licensed producers, regulators, insurers and prescribers to support medicine registration claims and ensure patients receive safe and effective cannabinoid medicines.

Expertise in cannabis

Emerald Clinics has to date entered into letters of intent to commercialise its anonymised clinical evidence with customers including Spectrum Therapeutics, the medical division of the world’s largest cannabis company, Canopy Growth, as set out in the Company’s IPO prospectus.

Joining the board in conjunction with the Company’s listing on the ASX is renowned UK based thought leader Sir Professor John Tooke, who brings 30 years’ experience as a clinician scientist and outstanding expertise from numerous board seats and university positions. This includes current roles as an Independent Director of BUPA Chile and Chairman of Collaboration for the Advancement of Sustainable Medical Innovation (CASMI), University College London.

Sir Tooke was also formerly an independent director of the BUPA main Board, Chair of the BUPA Medical Advisory Council, Head of the School of Life and Medical Sciences at University College London, past President of the Academy of Medical Sciences in the UK, a director at the Francis Crick Institute, a Member of the Council for Science & Technology reporting to the Prime Minister (UK) and served as a member of Google DeepMind Health’s Independent Review Board.

He was knighted in the UK in 2007 for services to medicine.

Emerald’s Managing Director and CEO Dr Michael Winlo, said: “With Emerald Clinics we have a unique and compelling business taking advantage of several emerging trends in digital health, clinical medicine and regulation science, and the funds raised in our IPO will allow us to build upon the early momentum we’ve achieved.

“We believe robust and ethically-sourced clinical evidence is vital for medicinal cannabis to be considered a mainstream medicine and Emerald is well positioned to be a key supplier of this information covering appropriate prescribing and safe monitoring.

“As well as welcoming new shareholders and thanking our existing shareholders for their continued support, I’d like to welcome Sir John Tooke to the board of the company, who brings a wealth of experience and will be integral to our plans to expand into the UK.”

Subscribe to our newsletter


Please enter your comment!
Please enter your name here